Relmada Therapeutics, Inc.
RLMD
$0.627
$0.0172.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -20.17% | -25.89% | -22.86% | -14.25% | -5.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.78% | -19.70% | -19.10% | -20.71% | -30.61% |
| Operating Income | 22.78% | 19.70% | 19.10% | 20.71% | 30.61% |
| Income Before Tax | 21.85% | 19.71% | 19.04% | 22.48% | 32.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 21.85% | 19.71% | 19.04% | 22.48% | 32.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.85% | 19.71% | 19.04% | 22.48% | 32.74% |
| EBIT | 22.78% | 19.70% | 19.10% | 20.71% | 30.61% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 23.17% | 20.04% | 19.22% | 22.59% | 32.81% |
| Normalized Basic EPS | 22.63% | 18.86% | 18.63% | 20.96% | 31.84% |
| EPS Diluted | 23.17% | 20.04% | 19.22% | 22.62% | 32.83% |
| Normalized Diluted EPS | 22.63% | 18.86% | 18.63% | 20.96% | 31.84% |
| Average Basic Shares Outstanding | 2.86% | 0.42% | 0.21% | 0.15% | 0.12% |
| Average Diluted Shares Outstanding | 2.86% | 0.42% | 0.21% | 0.15% | 0.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |